DD284046A5 - Verfahren zur herstellung eines aids-diagnostikums - Google Patents
Verfahren zur herstellung eines aids-diagnostikums Download PDFInfo
- Publication number
- DD284046A5 DD284046A5 DD87329441A DD32944187A DD284046A5 DD 284046 A5 DD284046 A5 DD 284046A5 DD 87329441 A DD87329441 A DD 87329441A DD 32944187 A DD32944187 A DD 32944187A DD 284046 A5 DD284046 A5 DD 284046A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- gene
- aids
- aids virus
- virus
- protein
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 43
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 122
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 45
- 241000238631 Hexapoda Species 0.000 claims abstract description 43
- 241000700605 Viruses Species 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 40
- 238000001514 detection method Methods 0.000 claims abstract description 11
- 238000009007 Diagnostic Kit Methods 0.000 claims abstract description 3
- 241000701447 unidentified baculovirus Species 0.000 claims description 44
- 239000013598 vector Substances 0.000 claims description 42
- 238000003780 insertion Methods 0.000 claims description 26
- 230000037431 insertion Effects 0.000 claims description 26
- 239000012634 fragment Substances 0.000 claims description 24
- 102100034353 Integrase Human genes 0.000 claims description 21
- 108010078428 env Gene Products Proteins 0.000 claims description 21
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims description 20
- 108090000288 Glycoproteins Proteins 0.000 claims description 19
- 102000003886 Glycoproteins Human genes 0.000 claims description 19
- 108700004025 env Genes Proteins 0.000 claims description 16
- 101150030339 env gene Proteins 0.000 claims description 16
- 101710182846 Polyhedrin Proteins 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 15
- 241000201370 Autographa californica nucleopolyhedrovirus Species 0.000 claims description 8
- 238000010367 cloning Methods 0.000 claims description 7
- 239000000032 diagnostic agent Substances 0.000 claims description 7
- 229940039227 diagnostic agent Drugs 0.000 claims description 7
- 238000004458 analytical method Methods 0.000 claims description 6
- 230000002163 immunogen Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 241000256251 Spodoptera frugiperda Species 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 108010034897 lentil lectin Proteins 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- 239000002250 absorbent Substances 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 108700004026 gag Genes Proteins 0.000 claims description 2
- 101150098622 gag gene Proteins 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 108700004029 pol Genes Proteins 0.000 claims description 2
- 101150088264 pol gene Proteins 0.000 claims description 2
- 239000000523 sample Substances 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 206010061598 Immunodeficiency Diseases 0.000 abstract description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract description 2
- 230000007813 immunodeficiency Effects 0.000 abstract description 2
- 230000009385 viral infection Effects 0.000 abstract description 2
- 238000012270 DNA recombination Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 40
- 150000001413 amino acids Chemical group 0.000 description 35
- 229940024606 amino acid Drugs 0.000 description 31
- 235000001014 amino acid Nutrition 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 29
- 238000003776 cleavage reaction Methods 0.000 description 27
- 230000007017 scission Effects 0.000 description 27
- 108020004705 Codon Proteins 0.000 description 22
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 108091081024 Start codon Proteins 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 238000001262 western blot Methods 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 229920001220 nitrocellulos Polymers 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 101710125418 Major capsid protein Proteins 0.000 description 7
- 239000000020 Nitrocellulose Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 101710132601 Capsid protein Proteins 0.000 description 6
- 101710094648 Coat protein Proteins 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 6
- 101710141454 Nucleoprotein Proteins 0.000 description 6
- 101710083689 Probable capsid protein Proteins 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241000700618 Vaccinia virus Species 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- 241000255777 Lepidoptera Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 229940124718 AIDS vaccine Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108091029865 Exogenous DNA Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 108010048209 Human Immunodeficiency Virus Proteins Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710132031 Mantle protein Proteins 0.000 description 1
- VSJAPSMRFYUOKS-IUCAKERBSA-N Met-Pro-Gly Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O VSJAPSMRFYUOKS-IUCAKERBSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001477931 Mythimna unipuncta Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 102000055647 human CSF2RB Human genes 0.000 description 1
- 102000053563 human MYC Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000001739 intranuclear inclusion body Anatomy 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000013031 physical testing Methods 0.000 description 1
- 108010089520 pol Gene Products Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 101150059999 pro gene Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000003156 radioimmunoprecipitation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6045—RNA rev transcr viruses
- C12N2810/6054—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92019786A | 1986-10-16 | 1986-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD284046A5 true DD284046A5 (de) | 1990-10-31 |
Family
ID=25443341
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD30803987A DD269629A5 (de) | 1986-10-16 | 1987-10-16 | Verfahren zur Herstellung von Proteinen des menschlichen Immundefizienz -Virus in mit rekombinanten Baculoviren infizierten Insekten-Zellen |
| DD87329440A DD283935A5 (de) | 1986-10-16 | 1987-10-16 | Verfahren zur herstellung eines aids-virus-impfstoffes |
| DD87329441A DD284046A5 (de) | 1986-10-16 | 1987-10-16 | Verfahren zur herstellung eines aids-diagnostikums |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD30803987A DD269629A5 (de) | 1986-10-16 | 1987-10-16 | Verfahren zur Herstellung von Proteinen des menschlichen Immundefizienz -Virus in mit rekombinanten Baculoviren infizierten Insekten-Zellen |
| DD87329440A DD283935A5 (de) | 1986-10-16 | 1987-10-16 | Verfahren zur herstellung eines aids-virus-impfstoffes |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0265785A3 (pl) |
| JP (1) | JPS63207397A (pl) |
| CN (1) | CN87107837A (pl) |
| AR (1) | AR241940A1 (pl) |
| AU (2) | AU7984287A (pl) |
| BR (1) | BR8705535A (pl) |
| DD (3) | DD269629A5 (pl) |
| DK (1) | DK541987A (pl) |
| FI (1) | FI874564A (pl) |
| HU (1) | HUT45095A (pl) |
| IE (1) | IE872748L (pl) |
| IL (1) | IL84154A0 (pl) |
| LT (3) | LTIP1793A (pl) |
| LV (1) | LV10654B (pl) |
| PL (2) | PL161165B1 (pl) |
| ZA (1) | ZA877752B (pl) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63258575A (ja) * | 1986-12-15 | 1988-10-26 | レプリゲン コーポレーション | 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク |
| IL85149A0 (en) * | 1987-01-27 | 1988-06-30 | Microgenesys Inc | Hiv gp160 aids virus envelope protein-containing substrates and methods for detection of aids antibody thereby |
| US5681713A (en) * | 1987-05-08 | 1997-10-28 | Smithkline Beecham Corporation | Expression of heterologous proteins in Drosophila cells |
| IL89118A0 (en) * | 1988-02-03 | 1989-08-15 | Microgenesys Inc | Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1 |
| IL90048A0 (en) * | 1988-04-25 | 1989-12-15 | Merck & Co Inc | Recombinant gag precursor of hiv,its preparation and its use as aids vaccine |
| JP2511494B2 (ja) * | 1988-05-12 | 1996-06-26 | 善治 松浦 | 日本脳炎ウイルス表面抗原蛋白質の製造法 |
| CA2003300A1 (en) * | 1988-11-21 | 1990-05-21 | Franklin Volvovitz | Skin test and test kit for aids |
| JP2852431B2 (ja) * | 1988-12-07 | 1999-02-03 | 財団法人阪大微生物病研究会 | レトロウイルスのプロテアーゼ、逆転写酵素及びエンドヌクレアーゼ、並びにこれ等の酵素の製法 |
| AU5187190A (en) * | 1989-02-23 | 1990-09-26 | University Of Ottawa | Improved baculovirus expression system capable of producing foreign gene proteins at high levels |
| US5194376A (en) * | 1989-02-28 | 1993-03-16 | University Of Ottawa | Baculovirus expression system capable of producing foreign gene proteins at high levels |
| AU5184190A (en) * | 1989-02-23 | 1990-09-26 | University Of Ottawa | Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine |
| DK0385909T3 (da) * | 1989-03-03 | 1994-08-15 | Microgenesys Inc | Kit eller middel til forebyggelse eller behandling af HIV-1-infektioner |
| EP0406857B1 (en) * | 1989-07-07 | 1995-05-24 | Takeda Chemical Industries, Ltd. | Proteins and production thereof |
| EP0421626A1 (en) * | 1989-09-19 | 1991-04-10 | Merck & Co. Inc. | Vaccine for aids and hepatitis B |
| US5346989A (en) * | 1990-08-22 | 1994-09-13 | Syntello Vaccine Development Kb | Peptides for use in induction of T cell activation against HIV-1 |
| DE69312485T2 (de) * | 1992-04-24 | 1998-01-15 | Us Health | Nachweis von maservirus-specifischer antikörpern durch gebrauch von rekombinanten maserproteinen |
| DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
| EP0979101B1 (en) | 1996-07-03 | 2010-10-27 | Merial, Inc. | Recombinant canine adenovirus 2 (cav2) containing exogenous dna |
| US6517843B1 (en) | 1999-08-31 | 2003-02-11 | Merial | Reduction of porcine circovirus-2 viral load with inactivated PCV-2 |
| US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
| JP2002030098A (ja) * | 2000-07-17 | 2002-01-29 | Institute Of Immunology Co Ltd | バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法 |
| AU2003275127A1 (en) | 2002-09-19 | 2004-04-08 | Merial Limited | P. ariasi polypeptides, p. perniciosus polypeptides and methods of use |
| EP1572968B1 (en) | 2002-10-29 | 2009-04-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Lutzomyia longipalpis polypeptides and methods of use |
| EP2390352A1 (en) | 2003-03-18 | 2011-11-30 | Quantum Genetics Ireland Limited | Systems and methods for improving protein and milk production of dairy herds |
| US7468273B2 (en) | 2003-05-01 | 2008-12-23 | Meial Limited | Canine GHRH gene, polypeptides and methods of use |
| US7556814B2 (en) * | 2003-10-23 | 2009-07-07 | Karp Nelson M | Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane |
| US20050214316A1 (en) | 2003-11-13 | 2005-09-29 | Brown Thomas P | Methods of characterizing infectious bursal disease virus |
| AU2005244673B2 (en) | 2004-02-19 | 2009-12-10 | The Governors Of The University Of Alberta | Leptin promoter polymorphisms and uses thereof |
| ES2343270T3 (es) | 2005-04-25 | 2010-07-27 | Merial Ltd. | Vacunas contra el virus nipah. |
| US20080241184A1 (en) | 2005-08-25 | 2008-10-02 | Jules Maarten Minke | Canine influenza vaccines |
| CA2629522A1 (en) | 2005-11-14 | 2007-05-18 | Merial Limited | Gene therapy for renal failure |
| US7771995B2 (en) | 2005-11-14 | 2010-08-10 | Merial Limited | Plasmid encoding human BMP-7 |
| US7862821B2 (en) | 2006-06-01 | 2011-01-04 | Merial Limited | Recombinant vaccine against bluetongue virus |
| GB2440528A (en) * | 2006-07-27 | 2008-02-06 | Ist Superiore Sanita | Antigen-antibody complexes |
| US8202967B2 (en) | 2006-10-27 | 2012-06-19 | Boehringer Ingelheim Vetmedica, Inc. | H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use |
| JP5867795B2 (ja) * | 2007-02-01 | 2016-02-24 | テーツェーエフ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 調節性ｔ細胞の特異的活性化ならびに喘息、アレルギー疾患、自己免疫疾患、移植片拒絶の治療および免疫寛容の誘導のためのその使用 |
| JP5309159B2 (ja) | 2008-01-09 | 2013-10-09 | コングク ユニバーシティ インダストリアル コーオペレーション コーポレーション | バキュロウイルスを利用したワクチン |
| MX2010012069A (es) | 2008-05-08 | 2010-12-14 | Merial Ltd | Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena. |
| DK2414386T3 (en) | 2009-04-03 | 2016-02-22 | Merial Ltd | Birds of vaccines with newcastle disease virus vectors |
| TWI627281B (zh) | 2009-09-02 | 2018-06-21 | 百靈佳殷格翰家畜藥品公司 | 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物 |
| WO2011119920A2 (en) | 2010-03-25 | 2011-09-29 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| PL2611460T3 (pl) | 2010-08-31 | 2017-02-28 | Merial, Inc. | Szczepionki przeciw herpeswirusom przenoszone z pomocą wirusa choroby newcastle |
| AR083533A1 (es) | 2010-10-22 | 2013-03-06 | Boehringer Ingelheim Vetmed | Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe |
| WO2012090073A2 (en) | 2010-12-30 | 2012-07-05 | The Netherlands Cancer Institute | Methods and compositions for predicting chemotherapy sensitivity |
| EP2694677A2 (en) | 2011-04-04 | 2014-02-12 | Netherland Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| WO2012138789A2 (en) | 2011-04-04 | 2012-10-11 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment |
| WO2012145577A1 (en) | 2011-04-20 | 2012-10-26 | Merial Limited | Adjuvanted rabies vaccine with improved viscosity profile |
| EP2701736A1 (en) | 2011-04-25 | 2014-03-05 | Advanced Bioscience Laboratories, Inc. | Truncated hiv envelope proteins (env), methods and compositions related thereto |
| ES2674439T3 (es) | 2011-06-01 | 2018-06-29 | Merial, Inc. | Administración sin aguja de vacunas contra el VSRRP |
| DK2691530T3 (en) | 2011-06-10 | 2018-05-22 | Univ Oregon Health & Science | CMV GLYCOPROTEIN AND RECOMBINANT VECTORS |
| AU2012284558B2 (en) | 2011-07-20 | 2017-06-29 | Centre National De La Recherche Scientifique | Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene |
| LT2741740T (lt) | 2011-08-12 | 2017-08-10 | Merial, Inc. | Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas |
| AR088028A1 (es) | 2011-08-15 | 2014-05-07 | Boehringer Ingelheim Vetmed | Proteinas h5, de h5n1 para un uso medicinal |
| WO2013033092A2 (en) | 2011-09-03 | 2013-03-07 | Boehringer Ingelheim Vetmedica Gmbh | Streptococcus suis pilus antigens |
| WO2013093629A2 (en) | 2011-12-20 | 2013-06-27 | Netherlands Cancer Institute | Modular vaccines, methods and compositions related thereto |
| WO2013138776A1 (en) | 2012-03-16 | 2013-09-19 | Merial Limited | Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g |
| SG11201405847SA (en) | 2012-03-20 | 2014-10-30 | Merial Inc | Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof |
| MX360137B (es) | 2013-02-21 | 2018-10-24 | Boehringer Ingelheim Vetmedica Gmbh | Proteínas h5 del virus de la influenza h5n1 para usarse como un medicamento. |
| WO2014164697A1 (en) | 2013-03-12 | 2014-10-09 | Merial Limited | Reverse genetics schmallenberg virus vaccine compositions, and methods of use thereof |
| JP6395855B2 (ja) | 2014-04-03 | 2018-09-26 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ブタ流行性下痢ウイルスワクチン |
| AU2015343369B2 (en) | 2014-11-03 | 2018-11-22 | Georgia Tech Research Corporation | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus |
| EA201890110A1 (ru) | 2015-06-23 | 2018-05-31 | Мериал, Инк. | Рекомбинантные вирусные векторы, содержащие минорные белки prrsv, и способы их получения и применения |
| DK3344289T3 (da) | 2015-08-31 | 2020-04-14 | Boehringer Ingelheim Vetmedica Gmbh | Pestivirusvacciner mod medfødt tremor |
| JP2018526454A (ja) | 2015-09-16 | 2018-09-13 | ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド | ブタコレラ菌−ネズミチフス菌ワクチン |
| WO2018057441A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | Canine adenovirus vectors |
| BR112019005418A2 (pt) | 2016-09-20 | 2019-10-01 | Boehringer Ingelheim Vetmedica Gmbh | novos promotores |
| KR102566066B1 (ko) | 2016-09-20 | 2023-08-16 | 베링거잉겔하임베트메디카게엠베하 | 신규한 돼지 인플루엔자 백신 |
| KR102618843B1 (ko) | 2016-09-20 | 2024-01-02 | 베링거잉겔하임베트메디카게엠베하 | 신규한 ehv 삽입 부위 orf70 |
| CA3042584A1 (en) | 2016-11-03 | 2018-05-11 | Boehringer Ingelheim Vetmedica Gmbh | Vaccine against porcine parvovirus and porcine reproductive and respiratory syndrome virus and methods of production thereof |
| BR112019009133A2 (pt) | 2016-11-03 | 2019-07-16 | Boehringer Ingelheim Vetmedica Gmbh | vacina contra o parvovírus suíno |
| CN110545841A (zh) | 2017-01-30 | 2019-12-06 | 勃林格殷格翰动物保健美国有限公司 | 猪冠状病毒疫苗 |
| KR20200027479A (ko) | 2017-07-12 | 2020-03-12 | 베링거 인겔하임 애니멀 헬스 유에스에이 인크. | 세네카바이러스 a 면역원성 조성물 및 이의 방법 |
| AR113124A1 (es) | 2017-09-23 | 2020-01-29 | Boehringer Ingelheim Vetmedica Gmbh | Sistema de expresión de paramyxoviridae |
| WO2019092027A1 (en) | 2017-11-09 | 2019-05-16 | Boehringer Ingelheim Vetmedica Gmbh | Sapelovirus immunogenic compositions and uses thereof |
| WO2019162294A1 (en) | 2018-02-23 | 2019-08-29 | Boehringer Ingelheim Vetmedica Gmbh | Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom |
| EP3768307A1 (en) | 2018-03-19 | 2021-01-27 | Boehringer Ingelheim Vetmedica GmbH | New ehv with inactivated ul18 and/or ul8 |
| AU2019239552A1 (en) | 2018-03-19 | 2020-09-10 | Boehringer Ingelheim Vetmedica Gmbh | EHV insertion site UL43 |
| EA202092216A1 (ru) | 2018-03-26 | 2021-06-11 | Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. | Способ получения иммуногенной композиции |
| EP3852800A1 (en) | 2018-09-20 | 2021-07-28 | Boehringer Ingelheim Vetmedica GmbH | Intranasal vector vaccine against porcine epidemic diarrhea |
| CN112867505B (zh) | 2018-09-20 | 2024-10-01 | 勃林格殷格翰动物保健有限公司 | 经修饰的pedv刺突蛋白 |
| WO2021158878A1 (en) | 2020-02-06 | 2021-08-12 | Boehringer Ingelheim Animal Health USA Inc. | Polypeptides useful for detecting anti-rhabdovirus antibodies |
| CN116438202A (zh) | 2020-10-05 | 2023-07-14 | 勃林格殷格翰动物保健美国有限公司 | 包含圆环病毒科衣壳蛋白的融合蛋白及其构成的嵌合病毒样颗粒 |
| EP4225776A1 (en) | 2020-10-05 | 2023-08-16 | Boehringer Ingelheim Vetmedica GmbH | Fusion protein useful for vaccination against rotavirus |
| AR128992A1 (es) | 2022-04-05 | 2024-07-03 | Boehringer Ingelheim Vetmedica Gmbh | Composición inmunógena útil para la vacunación contra el rotavirus |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3485810T2 (de) * | 1983-05-27 | 1992-12-10 | Texas A & M University Syst | Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. |
| ZA867281B (en) * | 1985-09-25 | 1987-05-27 | Oncogen | Vaccines and immunoassays for acquired immune deficiency syndrome |
| GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
| KR950001993B1 (ko) * | 1985-12-18 | 1995-03-08 | 마이크로제네시스,인코포레이티드 | B형 간염 표면항원의 제조방법 |
| JPS63258575A (ja) * | 1986-12-15 | 1988-10-26 | レプリゲン コーポレーション | 昆虫細胞中でつくられる組換えｈｉｖエンベロープタンパク |
-
1987
- 1987-10-13 IE IE872748A patent/IE872748L/xx unknown
- 1987-10-13 IL IL84154A patent/IL84154A0/xx unknown
- 1987-10-15 EP EP87115085A patent/EP0265785A3/en not_active Withdrawn
- 1987-10-15 ZA ZA877752A patent/ZA877752B/xx unknown
- 1987-10-16 CN CN198787107837A patent/CN87107837A/zh active Pending
- 1987-10-16 HU HU874666A patent/HUT45095A/hu unknown
- 1987-10-16 DD DD30803987A patent/DD269629A5/de not_active IP Right Cessation
- 1987-10-16 PL PL1987268266A patent/PL161165B1/pl unknown
- 1987-10-16 DD DD87329440A patent/DD283935A5/de not_active IP Right Cessation
- 1987-10-16 AU AU79842/87A patent/AU7984287A/en not_active Abandoned
- 1987-10-16 DD DD87329441A patent/DD284046A5/de not_active IP Right Cessation
- 1987-10-16 JP JP62262572A patent/JPS63207397A/ja active Pending
- 1987-10-16 AR AR87308981A patent/AR241940A1/es active
- 1987-10-16 BR BR8705535A patent/BR8705535A/pt unknown
- 1987-10-16 PL PL1987293520A patent/PL161448B1/pl unknown
- 1987-10-16 FI FI874564A patent/FI874564A/fi not_active IP Right Cessation
- 1987-10-16 DK DK541987A patent/DK541987A/da not_active Application Discontinuation
-
1991
- 1991-11-29 AU AU88324/91A patent/AU8832491A/en not_active Abandoned
-
1993
- 1993-05-14 LV LVP-93-344A patent/LV10654B/xx unknown
-
1994
- 1994-01-24 LT LTIP1793A patent/LTIP1793A/xx not_active Application Discontinuation
- 1994-01-24 LT LTIP1792A patent/LTIP1792A/xx unknown
- 1994-01-24 LT LTIP1794A patent/LTIP1794A/xx not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| PL161448B1 (pl) | 1993-06-30 |
| IE872748L (en) | 1988-04-16 |
| DK541987A (da) | 1988-04-17 |
| FI874564A (fi) | 1988-04-17 |
| LTIP1792A (en) | 1995-08-25 |
| LV10654B (en) | 1995-10-20 |
| JPS63207397A (ja) | 1988-08-26 |
| ZA877752B (en) | 1989-06-28 |
| DD269629A5 (de) | 1989-07-05 |
| FI874564A0 (fi) | 1987-10-16 |
| LV10654A (lv) | 1995-04-20 |
| LTIP1793A (en) | 1995-08-25 |
| AR241940A1 (es) | 1993-01-29 |
| LTIP1794A (en) | 1995-08-25 |
| EP0265785A3 (en) | 1989-11-08 |
| CN87107837A (zh) | 1988-12-21 |
| IL84154A0 (en) | 1988-03-31 |
| DK541987D0 (da) | 1987-10-16 |
| DD283935A5 (de) | 1990-10-31 |
| HUT45095A (en) | 1988-05-30 |
| AU8832491A (en) | 1992-04-30 |
| EP0265785A2 (en) | 1988-05-04 |
| PL268266A1 (en) | 1988-08-18 |
| BR8705535A (pt) | 1988-05-24 |
| PL161165B1 (pl) | 1993-05-31 |
| AU7984287A (en) | 1988-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DD284046A5 (de) | Verfahren zur herstellung eines aids-diagnostikums | |
| DE69033896T2 (de) | Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten | |
| DE3853422T2 (de) | HIV-3-Retrovirus und seine Verwendung. | |
| DE3588134T2 (de) | Fusionen von AIDS-verwandten Polypeptiden | |
| DE68929478T2 (de) | Rekombinante CMV-Neutralisierungsproteine | |
| DE3588251T2 (de) | DNS-Fragmente des GAG-Gens von LAV | |
| DE68918867T2 (de) | Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen. | |
| DE3711016C2 (pl) | ||
| DE69333814T2 (de) | Genetischer impfstoff gegen den immunschwäche virus | |
| DE3750782T2 (de) | Zellinie, die virale Aids-Antigene produziert, ohne infektiöse Viruspartikel zu produzieren. | |
| EP0495896B1 (de) | Vakzine zum schutz vor hiv-virusinfektionen, verfahren zu ihrer herstellung und ihre verwendung als diagnostikum und immuntherapeutikum | |
| DE69938062T2 (de) | Modifizierte hiv env polypeptide | |
| DE69131513T2 (de) | Für abgeänderte retrovirale GAG-Polypeptide kodierende DNA-Sequenzen und diese enthaltende Impfstoffe oder Aggregate davon | |
| DE3788806T2 (de) | Kugelförmige hybrid-hiv-antigene. | |
| DE69322872T2 (de) | Vakzine gegen immunodefizienz-virus der katze (kiv) | |
| DE3788807T2 (de) | Fusionsproteine und -partikel. | |
| DE3789400T2 (de) | Für ein Glykoprotein des AIDS-Virus kodierende Virus-Vektoren, Vakzin und Antikörper. | |
| DE69223952T2 (de) | Entwurf, Konstruktion und Expression von chimärischen Proteinen zur Entwicklung von Impfstoffen und diagnostischen Reagenzien | |
| EP0727483B1 (de) | Retrovirus aus der HIV-Gruppe und dessen Verwendung | |
| DE3650011T2 (de) | EXPRESSION UND DIAGNOSE MIT gag-KODIERTEN PEPTIDEN, DIE MIT ANTIKÖRPERN GEGEN LAV IMMUNOLOGISCH REAKTIV SIND. | |
| DE69131992T2 (de) | Papillomavirusuntereinheit-impfstoff | |
| DE69007099T2 (de) | Synthetisches peptid für einen hiv-1 impfstoff. | |
| DE69019359T3 (de) | Menschliche parvovirus-b19-proteine und virusähnliche partikeln, deren herstellung sowie deren verwendung in diagnostischen tests und in impfstoffen. | |
| DE69231705T2 (de) | Gag-Env Fusion-Antigen aus HIV | |
| DE69432730T2 (de) | Rekombinante Adenovirus-Vakzinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |